IMPACT THERAP-B(07630.HK)

IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC). Its pipeline products includes IMP1734, a next-generation poly (ADP-ribose) polymerase (PARP)1 selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; IMP9064, an ataxia telangiectasia and Rad3-related kinase selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for advanced solid tumors; IMP1707, a central nervous system penetrant, PARP1 selective inhibitor, which is in Phase I clinical trial for homologous recombination repair tumors; and IMP7068, and advanced WEE1 inhibitor, which is in Phase I/II clinical trial for advanced solid tumors. The company also develops IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, which are in preclinical stage.